Lipopeptide vaccines - EQiTX

Drug Profile

Lipopeptide vaccines - EQiTX

Alternative Names: VacTX

Latest Information Update: 12 Nov 2009

Price : $50

At a glance

  • Originator EQiTX
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Autoimmune disorders; Bacterial infections; Cancer; Hypersensitivity; Prostate cancer; Viral infections

Most Recent Events

  • 21 Mar 2006 Phase-I clinical trials in Viral infections in Australia (unspecified route)
  • 03 Aug 2005 Early research in Bacterial infections in Australia (unspecified route)
  • 03 Aug 2005 Early research in Viral infections in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top